Organic Active Ingredients TRIZ Cases

Cyclic glycyl proline analogs treat underlying neurological causes of autism by normalizing social behavior and reducing hyperactivity.

Non-lytic aerolysin binds GPI anchors to quantify PNH Type II cells, resolving unreliable diagnostics caused by red blood cell turnover.

Angiotensin II reduces cardiac injury by lowering troponin levels and minimizing catecholamine exposure during vasodilatory shock treatment.

Topical diene compounds inhibit UV-induced DNA damage, preventing skin cancer by preserving cell viability.

A VEGF-B inhibitor compound reduces stroke damage by blocking specific signaling pathways.

Therapeutic heterocyclic compounds block IDO1-mediated immunosuppression to improve prognosis in cancer and chronic infections.

Direct modified release coating on band-sealed gelatin capsules eliminates precoating steps.

Drying a nucleic acid and cationic lipid mixture into a solid tablet removes sterile preparation constraints while maintaining biological activity.

Antagonist antibodies block netrin-1 and UNC5B receptors to remove retained macrophages from atherosclerotic plaques, resolving chronic inflammation.

An interferon alpha-Fc conjugate extends half-life and reduces chemotherapy side effects by enabling lower gemcitabine doses.

Incorporating artificial Ds-Da nucleotides into DNA aptamers improves binding affinity and stability for cancer detection applications.

Cereblon-associated proteins predict immunomodulatory compound sensitivity in diffuse large B-cell lymphoma and multiple myeloma patients.

Optimizing crystallization conditions for chidamide crystal form A resolves impurity issues, ensuring stable bioavailability.

Pyrazolo[3,4-d]pyrimidinone compounds selectively inhibit DAPKs and PIM kinases to treat cancers lacking effective targeted therapies.

Chimeric polynucleotide formulations incorporate amino acids to enhance protein production efficiency and stability.

Combining aldosterone with NSAIDs reduces hormone dosage while maintaining therapeutic effectiveness against presbycusis.

A metal oxide nanoparticle core coated with a cationic lanthanide shell linked to a polymer and pentamidine drug molecule.

Modified small molecules reduce parasite numbers while lowering toxicity to overcome drug-resistant strains.

Esters merge retinoid and bakuchiol moieties to enhance skin health while maintaining formulation versatility.

Molecularly dispersing the ERK inhibitor in HPMCAS overcomes low solubility to enhance pharmacokinetic profiles.

Cinnamoyl-piperazine derivatives antagonize PAR-1 receptors, resolving the trade-off between antithrombotic efficacy and bleeding risk.

A PLGA copolymer matrix embeds metalloporphyrins to enable sustained intratumoral drug diffusion.

Acid-free granulation stabilizes statins and ACE inhibitors, resolving chemical incompatibility while maintaining patient compliance.

Antisense oligonucleotides induce exon skipping in SLC7A11 pre-mRNA to reduce cystine/glutamate antiporter expression and limit cancer cell proliferation.

Encapsulating decitabine in biodegradable nanogels protects the drug from degradation while enabling controlled release to overcome tumor resistance.

Radiation-inactivated blood serum eye drops replace artificial tears lacking essential tear components.

Anti-CD5 antibodies selectively deplete CD5+ immune cells, preventing graft rejection and facilitating stem cell engraftment without broad immunosuppression.

Zwitterionic chitosan derivatives shield cationic PAMAM dendrimers, suppressing immune activation and inflammatory responses during parenteral administration.

TRAP-targeting nanoparticles concentrate azeliragon at injury sites during early healing phases, reducing scar tissue formation.

Histamine H4 receptor antagonists reverse cognitive deficits by shifting microglia from harmful to beneficial states, clearing amyloid plaques.

A luminescent compound selectively inhibits cancer stem cells and enables their detection through specific chemical properties.

Combining beta-caryophyllene with antipsychotics addresses chronic negative symptoms through multi-target therapeutic efficacy.

Formula I retinoid compounds improve tumor cell inhibition rates by substituting hydrogen atoms with functional groups at specific positions.

Combining systemic curcuminoids with specific irradiance overcomes low bioavailability to achieve high PASI reduction.

SUL-138 chromanol compounds target amyloid-beta polymerization to reduce plaque load while improving memory function and synaptic connectivity.

A tadalafil powder formulation uses xanthan gum to create a stable aqueous suspension for oral administration.

Selective MK2 inhibitors address safety concerns in p38 MAPK treatment by optimizing potency through parameter changes.

Formula I compounds antagonize the mineralocorticoid receptor, addressing suboptimal therapeutic effectiveness in hypertension and heart failure.

An anti-ITGA6/B4 antibody blocks cancer cell adhesion to bone marrow niches.

A liposomal topical formulation delivers finasteride into the scalp via a hydrogel matrix, reducing systemic side effects from oral administration.

Dupilumab blocks Th2 inflammation to lower nasal polyp volume and improve airflow without the recurrence rates of corticosteroid therapy.

Terminally activated monofunctional polyoxazoline derivatives enable stable conjugation to target molecules under diverse reaction conditions.

A bicyclic pyridine compound inhibits placental leucine aminopeptidase to preserve endogenous arginine-vasopressin levels.

Optimized dosing schedules for anti-Trop-2 antibody-drug conjugates deliver targeted therapeutic efficacy.

Pyrazolopyridinone compounds overcome resistance from gatekeeper mutations in FGFRs, maintaining therapeutic efficacy against altered signaling pathways.

Targeting EGFR signaling with inhibitors like cetuximab reduces fungal damage and prolongs survival without nephrotoxicity.

Iron crosslinks multiblock copolymer micelles to encapsulate insoluble SN-38, resolving solubility and toxicity trade-offs.

17-alpha hydroxyprogesterone caproate formulations mitigate proinflammatory responses and respiratory conditions associated with cytokine storms.

Substituted 2-aminopyridine derivatives inhibit ALK kinase to overcome drug resistance in non-small cell lung carcinoma.

Recessed male luer releases chlorhexidine acetate upon insertion, forming a lethal precipitate on female connector surfaces to prevent microbial ingress.

L-carnitine administration improves cognitive performance and reduces mental fatigue in healthy individuals through targeted metabolic support.

Formula I compounds inhibit PRMT1 activity via localized binding, resolving selectivity trade-offs against other methyltransferases.

Bicyclic heteroaryl compounds selectively inhibit PAR4-mediated platelet activation, reducing bleeding risks associated with traditional antiplatelet therapies.

Stereochemically enriched lipid compositions resolve the trade-off between mRNA delivery efficiency and toxicity by controlling stereoisomer purity.

A 3,5-disubstituted benzene alkynyl compound inhibits fibroblast growth factor receptor activity.

Compounds targeting NEK7 kinase overcome limited mechanism understanding by directly inhibiting the NLRP3 inflammasome for inflammatory disease treatment.

Substituted pyrazole compounds disrupt energy metabolism and reduce glutathione synthesis to treat hyperproliferative disorders with mutant KRAS genes.

Derivatized gemcitabine prodrugs improve room temperature stability while reducing gastrointestinal toxicity.

TGF-beta signal inhibiting agents block extracellular matrix deposition to treat Fuchs' endothelial corneal dystrophy without donor cornea waiting times.

Chondroitin sulfate and hyaluronan instillation lubricates urinary tract stones to facilitate passage while reducing lithotripsy-induced pain.

Pyk2 inhibitors enhance microglial clearance of beta-amyloid proteins, addressing the lack of effective preventive treatments for Alzheimer's disease.

Encapsulating microRNA hsa-miR-182-3p in lipid nanoparticles enables specific regulation of TRF2 expression.

Dexibuprofen addresses TECPR2-related Hereditary Spastic Paraparesis by suppressing specific gene expressions linked to autophagy dysfunction.

Benzoxazole entities resolve selectivity trade-offs by targeting unique active site residues for potent neurological treatment.

Allele specific PCR detects MYD88 mutations to distinguish lymphoplasmacytic lymphoma from other B cell neoplasms.

Substituted quinazoline compounds resolve oral bioavailability and blood-brain barrier penetration contradictions while maintaining selective p70S6K inhibition.

Substituted indazole derivatives inhibit protein kinases like ALK and IGF-1R, addressing inadequate therapeutic outcomes from non-specific treatments.

Crystalline monohydrochloride salt forms of a PI3K inhibitor resolve manufacturing complexity and yield issues through controlled phase transitions.

Administering once-daily 300 mg niraparib improves survival and response rates by targeting biallelic DNA-repair anomalies in heavily pre-treated mCRPC.

Liposome nanoemulsions boost compound bioavailability while solid binders prevent toxin reabsorption in the bowel.

A mucoadhesive ketamine formulation gels instantly on oral mucous membranes to enable non-injectable pain treatment.

Synthetic production of highly purified (+)-cis-THC overcomes low natural occurrence to treat epilepsy.

Soybean cultivar SCEL-1 extract containing specific flavonoid ratios reduces reactive oxygen species in skin and lung tissues.

Amorphous solid salts of cobicistat eliminate inert carrier particles to reduce formulation weight while maintaining rapid drug release.

Novel tricyclic compounds inhibit covalently closed circular DNA to treat hepatitis B.

Tucatinib inhibits mutant HER2 kinase activity, resolving limited clinical success from inadequate biological understanding of driver mutations.

Selective BLT2 agonists reduce inflammation through targeted receptor binding while preserving wound healing speed and minimizing adverse side effects.

Novel crystalline forms of fused amino pyridines resolve stability and solubility trade-offs in HSP90 inhibitors, enhancing pharmaceutical formulation efficacy.

Small molecule RAD51 inhibitors reduce protein activity, sensitizing cancer cells to chemotherapy while sparing normal tissue function.

Topical sodium thiosulfate formulations degrade sulfur mustard on skin surfaces, bypassing impractical intravenous injection requirements.

A bioresorbable implantable device releases chemotherapeutic agents through a mesh or shell structure to maintain effective drug concentrations.

Structurally simplified gambogic acid analogues overcome production complexity while maintaining strong anti-tumor efficacy.

An aqueous solution with solubilizing agents replaces dry powder to increase lung deposition from 20% to 60% while maintaining stability.

A 2-phenylbenzofuran derivative suppresses nitric oxide, IL-6, and TNF-alpha production.

Local rectal delivery of GM-CSF with fosfomycin treats inflammatory bowel disease lesions while avoiding systemic adverse effects.

Novel proinsulin-derived peptides induce regulatory T cell responses to halt autoimmune destruction of insulin-producing beta cells.

Nitrogen-containing cyclic compounds act as EP4 receptor agonists to stimulate osteogenesis, reducing side effects from existing treatments.

Twice-weekly intermittent dosing of a 3,5-disubstituted benzene alkynyl compound maintains antitumor efficacy while reducing blood phosphorus levels.

Isolating the (R)-enantiomer of fadrozole achieves 24-hour aldosterone suppression without aromatase inhibition side effects.

Pyrazolyl-pyridine compounds activate M4 muscarinic receptors via allosteric modulation, avoiding dose-limiting side effects from nonselective agonists.

New esters of N-acyl amino acid derivatives and aliphatic diols protect endothelial cells from oxidative stress.

Novel alkaloids induce autophagic cell death in cancer cells and clear mutant huntingtin proteins via AMPK-mTOR signaling pathways.

Pyrazolo-pyrrolo-pyrimidine-dione compounds target the P2X3 receptor to treat neurogenic disorders.